Microsaic Systems Plc (LON:MSYS) CEO Glenn Tracey talks to DirectorsTalk about its full year results for the year ended 31st Dec 2017. Glenn talks us through the highlights, explains how he sees the business growing both short and long term, realigning the primary focus of the Company on applications in the growing biopharma market, commercialising a strong IP portfolio and explains the group strategy for the next 12 months.
Microsaic Systems plc is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (“MS”) instruments that are designed to improve the efficiency of pharmaceutical R&D. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors. The company’s core product, the 4000 MiD(R), is one of the smallest MS systems in the world, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs.
